A fund manager and its managing member report a 9.99% stake in Citius Oncology (CTOR).
Alpha Vantage · Stock Titan · · AI-summarised by FinFlash
Armistice Capital, LLC and its managing member, Steven Boyd, have reported a 9.99% beneficial ownership stake in Citius Oncology, Inc. (CTOR), totaling 9,394,202 common shares as of September 30, 2026. The shares are directly held by Armistice Capital Master Fund Ltd., with Armistice Capital serving as its investment manager, exercising shared voting and dispositive power.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.